Plasma lipid composition and risk of developing cardiovascular disease.

Fernandez, Celine; Sandin, Marianne; Sampaio, Julio L; Almgren, Peter; Narkiewicz, Krzysztof; Hoffmann, Michal; Hedner, Thomas; Wahlstrand, Björn; Simons, Kai; Shevchenko, Andrej; James, Peter; Melander, Olle

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0071846

2013

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Plasma Lipid Composition and Risk of Developing Cardiovascular Disease

Celine Fernandez1*, Marianne Sandin2, Julio L. Sampaio3, Peter Almgren1, Krzysztof Narkiewicz4, Michal Hoffmann4, Thomas Hedner5, Björn Wahlstrand5, Kai Simons3, Andrej Shevchenko3, Peter James2, Olle Melander1*

1Department of Clinical Sciences, Lund University, Malmö, Sweden, 2Department of Immunotechnology, Lund University, Lund, Sweden, 3Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany, 4Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland, 5Department of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

Abstract

Aims: We tested whether characteristic changes of the plasma lipidome in individuals with comparable total lipids level associate with future cardiovascular disease (CVD) outcome and whether 23 validated gene variants associated with coronary artery disease (CAD) affect CVD associated lipid species.

Methods and Results: Screening of the fasted plasma lipidome was performed by top-down shotgun analysis and lipidome compositions compared between incident CVD cases (n = 211) and controls (n = 216) from the prospective population-based MDC study using logistic regression adjusting for Framingham risk factors. Associations with incident CVD were seen for eight lipid species (0.21 ≤ q ≤ 0.23). Each standard deviation unit higher baseline levels of two lysophosphatidylcholine species (LPC), LPC16:0 and LPC20:4, was associated with a decreased risk for CVD (P = 0.024–0.028). Sphingomyelin (SM) 38:2 was associated with increased odds of CVD (P = 0.057). Five triglyceride (TAG) species were associated with protection (P = 0.031–0.049). LPC16:0 was negatively correlated with the carotid intima-media thickness (P = 0.010) and with HbA1c (P = 0.012) whereas SM38:2 was positively correlated with LDL-cholesterol (P = 0.010) and the q-values were good (q ≤ 0.03). The risk allele of 8 CAD-associated gene variants showed significant association with the plasma level of several lipid species. However, the q-values were high for many of the associations (0.015 ≤ q ≤ 0.75). Risk allele carriers of 3 CAD-loci had reduced level of LPC16:0 and/or LPC 20:4 (P < 0.056).

Conclusion: Our study suggests that CVD development is preceded by reduced levels of LPC16:0, LPC20:4 and some specific TAG species and by increased levels of SM38:2. It also indicates that certain lipid species are intermediate phenotypes between genetic susceptibility and overt CVD. But it is a preliminary study that awaits replication in a larger population because statistical significance was lost for the associations between lipid species and future cardiovascular events when correcting for multiple testing.


Editor: Stefan Kiechl, Innsbruck Medical University, Austria

Received: January 11, 2013; Accepted: July 4, 2013; Published: August 15, 2013

Copyright: © 2013 Fernandez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Dr Fernandez is the holder of an European Society of Hypertension fellowship and was supported by the Royal Physiographic Society in Lund. Prof Melander was supported by grants from the European Research Council (StG-282255), the Swedish Medical Research Council, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University, Malmö University Hospital, the Albert Påhlsson Research Foundation, the Crafoord Foundation, the Ernhold Lundstroms Research Foundation, the Region Skane, the Huulda and Conrad Mossfelt Foundation, the King Gustaf V and Queen Victoria Foundation, the Lennart Hansson’s Memorial Fund, the Wallenberg Foundation, the Polish-Norwegian Research Fund and the CareNorth consortium. Dr Shevchenko is supported by TRR 83 grant from Deutsche Forschungsgemeinschaft and Virtual Liver grant (Code/0315757) from Bundesministerium f. Bildung u. Forschung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Celine.Fernandez@med.lu.se (CF); Olle.Melander@med.lu.se (OM)

Introduction

Cardiovascular mortality and morbidity is a major public health problem in Western societies. Traditional cardiovascular risk factors do not fully explain future cardiovascular events [1,2] and adding modern biomarkers to the standard risk factors has, thus so far, only proven to minimally improve individual risk prediction [3,4], thus underlining the need to identify new biomarkers.

Lipids are thought to play a central role in cardiovascular disease (CVD) development and total plasma triglycerides and cholesterol as well as LDL- and HDL-cholesterol are traditionally monitored as predictors of cardiovascular events. However, those are crude measurements of the sum of a complex composition of lipids and do not at all reflect other potentially atherogenic lipid species. We here hypothesized that specific plasma lipid species, rather than the rough phenotype of total triglycerides and cholesterol may be altered in subjects who develop CVD later in life, implying that they may be involved in the CVD pathogenesis.

Lipidomics, a subset within the field of metabolomics, strives to quantitatively describe the complete set of all lipids in a given cell type, tissue or biologic fluid of interest at a given time [5]. There is no single instrument or approach that can currently do so, but
Instead of multiple and often complementary analytical approaches can be employed. Typically, global lipid profiling is conducted by directly infusing a crude lipid extract into the mass spectrometer without prior chromatographic separation, also called shotgun technique [6], or by using on-line liquid chromatographic separation prior mass spectrometry (MS) analysis [7]. Lipidomic analyses for human biomarker discovery using either approach are now emerging [8–10].

Shotgun lipidomics which allows high-throughput, high intersample reproducibility, high sensitivity and ease of automation [11] was here used for screening of the plasma lipidome in a case-control material derived from a prospective population-based cohort study with similar plasma total lipids level. A top-down approach where individual lipid species are identified by accurately determining precursor masses with no recourse to tandem MS was implemented as previously described [8,12].

Because the mechanisms underlying CVD for most of the reported CVD-associated gene variants are unknown, we also tested whether the plasma lipidome associates with 23 well-validated gene variants for risk of coronary artery disease [13].

Materials and Methods

Ethics Statement

The Malmo Diet and Cancer study was approved by the Ethics Committee at Lund University and all participants provided written informed consent.

Study Participants and Data Collection

The Malmo Diet and Cancer (MDC) study is a population-based, prospective epidemiologic cohort consisting of 28,449 individuals who attended a baseline examination between 1991 and 1996 [14]. From the MDC cohort, 6,103 persons were randomly selected and asked to participate in a cardiovascular cohort study with similar plasma total lipids level. A top-down approach where individual lipid species are identified by accurately determining precursor masses with no recourse to tandem MS was implemented as previously described [8,12].

Because the mechanisms underlying CVD for most of the reported CVD-associated gene variants are unknown, we also tested whether the plasma lipidome associates with 23 well-validated gene variants for risk of coronary artery disease [13].

Materials and Methods

Ethics Statement

The Malmo Diet and Cancer study was approved by the Ethics Committee at Lund University and all participants provided written informed consent.

Study Participants and Data Collection

The Malmo Diet and Cancer (MDC) study is a population-based, prospective epidemiologic cohort consisting of 28,449 individuals who attended a baseline examination between 1991 and 1996 [14]. From the MDC cohort, 6,103 persons were randomly selected and asked to participate in a cardiovascular cohort (MDC-CC) between 1991 and 1994, which was designed to study the epidemiology of carotid artery disease [15,16]. All participants underwent a medical history assessment, a physical examination and a laboratory assessment of cardiovascular risk factors, including blood pressure, presence of diabetes mellitus (ascertained from self-reporting, or use of anti-diabetic medication, or fasting whole blood glucose >6.1 mM), smoking status, antihypertensive medication, a fasted lipid profile, C-reactive protein (CRP) and measurement of the common carotid intima-media thickness (IMT) by ultrasound [16,17]. 23 validated gene variants associated with coronary artery disease (CAD) [13,18–20] were genotyped (Supplementary Table S6). Genotyping was performed using SEQUENOM MassARRAY® Designer software and oligonucleotides were provided by Metabion (Martinsried, Germany). Assays were performed on the SEQUENOM MALDI-Tof mass spectrometer (San Diego, CA) using iPLEX reagents and protocols and 10 ng DNA as PCR template.

During a mean follow-up time of 12.2±2.3 years [21], 364 first incident cardiovascular events (myocardial infarction, ischemic stroke and death from coronary heart disease) with complete baseline clinical information were ascertained from three registries: the Swedish Hospital Discharge Register, the Swedish Cause of Death Register and the Stroke Register of Malmo, as previously described [17]. We matched incident cardiovascular disease (CVD) cases with CVD free control subjects based on gender, age (±1 year) and Framingham risk score [22] (<0.1% difference in 10 year estimated risk) and also required that the follow-up time of the control was at least as long as that of the corresponding incident CVD case. These criteria resulted in successful matching of 253 CVD cases with 253 controls. Out of those, plasma was missing for 46 individuals. Moreover, 45 samples were lost after lipid extraction. This left 211 CVD cases and 216 controls for lipid profiling.

Materials, Chemicals and Lipid Standards

Material resistant to organic solvent was used (e.g. polypropylene, silicone, Teflon). Synthetic lipid standards were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) or Lardian Fine Chemicals (Malmo, Sweden). Methyl-tert-butylether (MTBE) and water (LiChrosolv grade) were purchased from Merck (Darmstadt, Germany). Methanol, chloroform and ammonium acetate (Liquid Chromatography grade) were purchased from Fluka (Buchs SG, Switzerland) and 2-propanol (ACS grade) from Sigma-Aldrich (Munich, Germany).

Table 1. Baseline characteristics of the study samples.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control (n = 216)</th>
<th>CVD case (n = 211)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.7±5.1</td>
<td>60.2±5.3</td>
<td>0.331</td>
</tr>
<tr>
<td>Women (%)</td>
<td>47.7</td>
<td>47.4</td>
<td>0.952</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.3±4.3</td>
<td>26.5±4.4</td>
<td>0.558</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>149.3±19.8</td>
<td>149.7±18.4</td>
<td>0.815</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>90.1±9.6</td>
<td>90.1±9.5</td>
<td>0.981</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>5.2±1.2</td>
<td>5.7±2.2</td>
<td>0.008</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>6.3±1.1</td>
<td>6.3±1.0</td>
<td>0.611</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.5±0.7</td>
<td>1.4±0.6</td>
<td>0.136</td>
</tr>
<tr>
<td>High density lipoprotein (mmol/l)</td>
<td>1.3±0.3</td>
<td>1.3±0.3</td>
<td>0.541</td>
</tr>
<tr>
<td>Low density lipoprotein (mmol/l)</td>
<td>4.3±1.0</td>
<td>4.4±1.0</td>
<td>0.426</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>8.3</td>
<td>15.2</td>
<td>0.028</td>
</tr>
<tr>
<td>Current smoker (%)</td>
<td>33.3</td>
<td>33.6</td>
<td>0.945</td>
</tr>
<tr>
<td>Anti-hypertensive treatment (%)</td>
<td>25.9</td>
<td>23.7</td>
<td>0.594</td>
</tr>
<tr>
<td>Lipid lowering drugs (%)</td>
<td>0.9</td>
<td>3.8</td>
<td>0.050</td>
</tr>
</tbody>
</table>

Values are mean±s.d. or percentage. P values were calculated using a t test for continuous variables and Pearson Chi-Square for binary variables.

doi:10.1371/journal.pone.0071846.t001
Lipid Profiling in Cardiovascular Disease

methanol 5/1.5 (v/v) providing a total of 2.7 nmol cholesteryl heptadecanoate (CE17:0), 0.7 nmol heptadecanoyl sphingomyelin (SM17:0), 3.5 nmol 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine (PC-O12:0/O12:0), 0.9 nmol 1,2-diO-phytanoyl-sn-glycero-3-phosphoethanolamine (PE-O16:0/O16:0), 3.1 nmol 1-lauroyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC12:0), 0.4 nmol N-heptadecanoyl-D-erythro-sphingosine (Cer17:0), 3.1 nmol tri- laurin (TAG12:0) and 0.5 nmol dilaurin (DAG12:0). Then 350 μL of MTBE/methanol 5:1.5 were added and the samples were shaken at 4°C for 1 h. Afterwards, 150 μL of water were added, followed by shaking at 4°C for 10 min and centrifugation for 5 min at 4,000 rpm on Rotanta 460R centrifuge (Hettich, Tuttlingen, Germany). The upper organic phase was transferred into a 96-well plate with glass inserts and a silicone/Teflon coated sealing mat (Chromacol) and stored at −20°C until performing the MS analysis for all the samples successively.

Figure 1. Quantification by top-down lipidomics correlates with clinical parameters. Linear regression analysis of A) the total triglyceride content or B) the total cholesterol content determined by MS versus the value obtained by traditional clinical chemistry analysis. The total triglyceride content measured by MS is obtained by summing the abundances of all the individual TAG species and the total cholesterol content by summing the abundances of free cholesterol and all cholesteryl esters. doi:10.1371/journal.pone.0071846.g001

Lipid Extraction

Overnight fasted citrate samples placed at −80°C immediately after collection, between 1991 and 1994, were analyzed. The samples had never been previously thawed. The samples were randomized before the lipid extraction step, which was carried out successively for all the samples. Lipid extraction was performed as previously described [23] but with adjustments in order to automate the procedure. In brief, 5 μL of plasma were manually pipetted into a 96-well plate (deep well plate from Axygen Scientific with ImperaMat) placed on ice whereas the following pipetting steps were performed at room temperature in a liquid-handling station (Beckman BiomekFX) using ART filter tips and polypropylene reagent reservoirs (FluidX). Samples were spiked with 350 μL of internal standard lipid mixture in MTBE/methanol 5/1.5 (v/v) containing 7.5 mM ammonium acetate and placed in a 96-well plate (Eppendorf) that was then sealed with aluminium foil (Corning). Shotgun analysis was performed on a LTQ Orbitrap (Thermo Fisher Scientific, Waltham, MA) coupled to a TriVersa NanoMate robotic nanoflow ion source (Advion BioSciences, Ithaca, NY) [8,12]. Samples were analyzed in duplicate. Lipids were identified and quantified using the LipidXplorer software [24] and lipid species of the following lipid classes were recognized: triacylglyceride (TAG), diacylglyceride (DAG), cholesteryl ester (Chol-FA), sphingomyelin (SM), phosphatidylcholine (PC), PC-ether (PC-O), lyso-PC (LPC), phosphatidylethanolamine (PE) and PE-ether (PE-O). Identification of the different lipid species was based on MS survey scans acquired in positive ion mode in the Orbitrap analyzer at a target mass resolution of 100,000 using a mass accuracy of better than 5 ppm and a signal to noise ratio of 2. Lipid species were quantified by normalizing the intensities of their peaks to the intensity of the peaks of internal standards spiked into the sample prior to lipid extraction. The internal standards were also used to monitor the quality of the MS analysis and representative mass spectra are presented (Supplementary Figure S1A and S1B). An internal standard mix was both extracted and run independently 18 times across the entire analysis to get an estimate of the coefficient of variation of the combined lipid extraction and MS analysis from the internal standards (Supplementary Table S1). The maximum value of duplicate samples was kept. Lipid species with >30% missing observations were excluded.

Statistical Analyses

SPSS (version 18.0) was used for all statistical analyses. Data were assessed for normality with histograms. Due to non-normality all the lipid species were log transformed prior analysis. All tests were two-sided and data were considered significant if P<0.05.

To determine the association of baseline individual lipid species with future CVD, we performed binary logistic regression adjusting for age, sex, diabetes, smoking status, LDL-cholesterol, HDL-cholesterol, systolic blood pressure (SBP), body mass index (BMI) and use of anti-hypertensive treatment.

Q-values were calculated using the QVALUE software [25]. Hierarchical clustering was performed with Euclidean distance and average linkage in MATLAB R2011a (version 7.12.0.635).
As a result of the initial matching procedure (age, gender and Framingham risk score) the baseline characteristics of the 211 incident cases of CVD and 216 control subjects were similar for most risk factors except fasted plasma glucose level and diabetes. The frequency of use of lipid lowering drugs was low (Table 1).

Lipid profiling was performed on samples obtained from the baseline examination that took place between 1991 and 1994. A total of 85 lipid species belonging to 9 major lipid classes were identified and quantified by the approach used (Supplementary Table S2). The total quantities of triglycerides and cholesterol determined by mass spectrometry were correlated with the values obtained by traditional clinical chemistry analysis (Figure 1 and Supplementary Figure S2). As known from previous study, the correlation was substantially stronger for triglycerides than for cholesterol [8].

### Table 2. Relation of baseline phospholipids level to future adverse cardiovascular outcome adjusting for Framingham risk factors.

<table>
<thead>
<tr>
<th>Model</th>
<th>LPC16:0 (n = 424)</th>
<th>LPC20:4 (n = 353)</th>
<th>SM38:2 (n = 318)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Models adjusting for sex, age, BMI, type 2 diabetes, anti-hypertension treatment, smoking, LDL, HDL and SBP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid specie as continuous variable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per s.d.</td>
<td>0.79 (0.65–0.97)</td>
<td>0.77 (0.61–0.96)</td>
<td>1.28 (0.99–1.64)</td>
</tr>
<tr>
<td>$P$</td>
<td>0.028</td>
<td>0.024</td>
<td>0.057</td>
</tr>
<tr>
<td>q-value</td>
<td>0.210</td>
<td>0.210</td>
<td>0.228</td>
</tr>
<tr>
<td>Lipid specie as categorical variable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First quartile</td>
<td>1.0 (referent)</td>
<td>1.0 (referent)</td>
<td>1.0 (referent)</td>
</tr>
<tr>
<td>Second quartile</td>
<td>1.21 (0.69–2.11)</td>
<td>1.13 (0.61–2.07)</td>
<td>0.94 (0.49–1.81)</td>
</tr>
<tr>
<td>Third quartile</td>
<td>0.94 (0.54–1.65)</td>
<td>0.62 (0.34–1.16)</td>
<td>1.320 (0.68–2.56)</td>
</tr>
<tr>
<td>Fourth quartile</td>
<td>0.57 (0.32–1.00)</td>
<td>0.62 (0.33–1.17)</td>
<td>1.85 (0.92–3.71)</td>
</tr>
<tr>
<td>$P$ for trend</td>
<td>0.032</td>
<td>0.048</td>
<td>0.054</td>
</tr>
</tbody>
</table>

Values are odds ratios (95% confidence intervals) for cardiovascular disease from multivariate adjusted binary logistic regressions performed with the Z score of a given lipid specie obtained after log transformation. BMI, body mass index; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; LPC, lysophosphatidylcholine; SBP, systolic blood pressure; SM, sphingomyelin.

doi:10.1371/journal.pone.0071846.t002

### Table 3. Relation of baseline triglycerides specie level to future adverse cardiovascular outcome adjusting for Framingham risk factors.

<table>
<thead>
<tr>
<th>Model</th>
<th>TAG48:1 (n = 424)</th>
<th>TAG48:2 (n = 424)</th>
<th>TAG48:3 (n = 402)</th>
<th>TAG50:3 (n = 424)</th>
<th>TAG50:4 (n = 423)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Models adjusting for sex, age, BMI, type 2 diabetes, anti-hypertension treatment, smoking, LDL, HDL and SBP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid specie as continuous variable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per s.d.</td>
<td>0.78 (0.63–0.98)</td>
<td>0.79 (0.64–0.98)</td>
<td>0.81 (0.65–1.00)</td>
<td>0.79 (0.63–0.98)</td>
<td>0.79 (0.64–0.98)</td>
</tr>
<tr>
<td>$P$</td>
<td>0.031</td>
<td>0.034</td>
<td>0.049</td>
<td>0.036</td>
<td>0.033</td>
</tr>
<tr>
<td>q-value</td>
<td>0.210</td>
<td>0.210</td>
<td>0.228</td>
<td>0.210</td>
<td>0.210</td>
</tr>
</tbody>
</table>

Values are odds ratios (95% confidence intervals) for cardiovascular disease from multivariate adjusted binary logistic regressions performed with the Z score of a given triacylglyceride specie obtained after log transformation. BMI, body mass index; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TAG, triacylglyceride.

doi:10.1371/journal.pone.0071846.t003
Coronary Artery Disease (CAD) and Plasma Lipid Profile

Association between Susceptibility Gene Variants and Plasma Lipid Profile

We examined the association of 23 well-validated CAD-associated gene variants with circulating concentrations of the various lipid species, including the one associating with CVD outcome (Supplementary material online, Table S6). Eight of the gene variants displayed statistically significant association with several lipid species (Supplementary material online, Table S7) and the lipid pattern associated with those loci is depicted in Figure 2. However, the q-values were high for many of the associations (0.015≤q≤0.75) (Supplementary material online, Table S8). The CAD-associated risk allele for the LPA gene variant distinguished itself by being strongly associated with increased baseline plasma level of total cholesterol (OR = 1.28; P = 0.057). Individuals in the top quartile of baseline total cholesterol had an increased risk of developing CVD (OR = 1.28; P = 0.054) (Table 2).

In the TAG class, plasma levels of TAG48:1, TAG48:2, TAG48:3, TAG50:3 and TAG50:4, were associated with decreased odds of future CVD (OR = 0.78–0.81; P = 0.031–0.049) (Table 3). However, the quartiles analysis showed poor linearity between the various TAGs and CVD risk (Supplementary material online, Table S4).

Different Correlation Patterns between the Various Plasma Lipid Classes and CVD Traditional Risk Factors

Partial correlations were performed between baseline lipid species levels and CVD risk factors (Table 4 and Supplementary material online, Figure S3) and the q-values for the statistically significant associations were good (1.29E-37 ≤ q ≤ 0.03) (Supplementary material online, Table S5). Few lipid species were correlated with carotid IMT, which in itself has previously been shown to predict incident coronary events, independently of cardiovascular risk factors [16], but all LPC species except one displayed negative correlation with the carotid IMT (P = 0.03). Correlation to the percentage of hemoglobin A1c (HbA1c) was seen mainly for the LPC and TAG species, with the former being negatively correlated (P = 0.01) and the later positively correlated (P = 0.03). Positive correlation to both LDL and HDL-cholesterol was observed for the majority of the glycerophospholipids with the exception of the LPC species which were only correlated to HDL-cholesterol (P = 0.04) (Supplementary material online, Figure S3).

The two CVD-protective LPC species, i.e., LPC16:0 and LPC20:4, were negatively correlated with BMI (P = 0.004) and positively correlated with HDL-cholesterol (P = 0.014) (Table 4). LPC16:0, but not LPC20:4, was negatively related to the carotid IMT and the percentage of HbA1c (P = 0.012). Also, LPC20:4 was negatively associated with SBP (P = 0.039). SM38:2, with a borderline P-value for increased association of future CVD odds, was positively correlated with LDL-cholesterol (P = 7.4E-11).

Association between Susceptibility Gene Variants for Coronary Artery Disease (CAD) and Plasma Lipid Profile

We examined the association of 23 well-validated CAD-associated gene variants with circulating concentrations of the various lipid species, including the one associating with CVD outcome (Supplementary material online, Table S6). Eight of the gene variants displayed statistically significant association with several lipid species (Supplementary material online, Table S7)
Figure 2. Association between the lipid profile and the risk allele of 8 CAD-associated gene variants. Heat map of regression coefficients obtained from linear regressions performed between the CAD-associated locus (with the CAD-associated allele coded) and the lipid species after log transformation adjusting for age and sex. *P<0.05, **P<0.01, ***P<0.001.
doi:10.1371/journal.pone.0071846.g002
Integrating Genomic and Lipidomics Information

Out of the 8 CAD susceptibility gene variants displaying significant association with circulating lipid species concentrations, 3 have not yet been previously reported to be involved in lipid metabolism (WDR12, ZC3HC1 and PHACTR1) and 3 are only known to affect lipoproteins levels (LPA, SORT1 and the ZNF259/APOA5-A4-C3-A1 gene region) [13,28]. However, any potential link between the genetic alteration of these lipids and CAD needs to be substantiated by mechanistic studies. Two of the 8 CAD loci are directly coding for enzymes involved in lipids biosynthesis (PPAP2B and the PEMT/RASD1/SMCR3 locus) [29,30]. The PPAP2B gene encodes a phosphatidic phosphatase that converts phosphatidic acid into diacylglycerol, the precursor for de novo synthesis of TAG, PC and PE. Moreover, PEMT encodes an enzyme which sequentially converts PE into PC. Both carriers of the PPAP2B and of the PEMT/RASD1/SMCR3 risk allele display reduced level of multiple glycerophospholipids including the CVD-protective lipid species LPC16:0 and/or LPC20:4. Overall, our findings highlight that integrating lipidomics with genomics is a promising approach to increase the understanding of mechanisms underlying the gene-CVD associations as well as CVD pathogenesis.

Study Limitations

This is an initial discovery study that needs to be replicated especially since the false discovery rate was high when looking for associations between the lipid species and future cardiovascular events or between the lipid species and most of the CAD-associated gene variants. Also, we do acknowledge that this is a case control study and not a general population study, thus the findings cannot be generalised to the whole population. Furthermore, our study could be complemented by acquiring spectra in negative ion mode to extend the lipid class coverage and by performing tandem MS for some targeted lipid species in order to get their full structural information. Another draw-back of the study is the lack of a pooled quality control plasma sample run across the study. Finally, we do not know to what extent the −80 degree Celsius storage over approximately 20 years may have affected the original lipid profile.

Conclusions

This study constitutes a proof-of-concept screen that shotgun lipidomics can be used as a tool in the search for novel CVD biomarkers. Moreover, we here highlight the importance of refining the dyslipidemia phenotype and thus looking at the level of individual lipid species rather than the total sum of the different lipid classes in their relationship with CVD risk. We identified some specific lipid species as potential biomarkers of adverse cardiovascular outcome. However, statistical significance was lost for the association between the lipid species and future cardiovascular events when correcting for multiple testing. Finally, our results support the informative value in bringing together genomic and lipidomics data, suggesting that certain individual lipid species are intermediate phenotypes between genetic susceptibility and overt CVD. Overall, this is an explorative study that will need to be replicated in a larger population.

Supporting Information

Figure S1 Representative mass spectra of total lipid extracts from plasma. The most abundant peaks are annotated with m/z; the shaded areas indicate the m/z ranges where the corresponding lipid classes were detected. (PDF)

Figure S2 Absolute quantification of TAGs by top-down lipidomics correlates with the total triglyceride levels measured at baseline examination. Linear regression was performed between the total absolute TAG levels determined by MS versus the total triglyceride levels measured by traditional clinical chemistry analysis. The total TAG level measured by MS is obtained by summing the abundances of all the individual TAG species. (PPT)

Figure S3 Different correlation patterns between the various plasma lipid classes and CVD traditional risk factors. Heat map of correlations coefficients obtained from partial correlations performed between the lipid species after log transformation and traditional laboratory predictors for cardiovascular disease adjusting for age and sex. *P<0.05, **P<0.01, ***P<0.001. (TIF)

Table S1 Coefficient of variation (CV) of the combined lipid extraction and MS analysis for the 8 internal standards. (DOCX)

Table S2 Absolute levels of the lipid species. (DOCX)

Table S3 A. Relation of baseline lipid species level to future adverse cardiovascular outcome adjusting for Framingham risk factors. B. Relation of baseline lipid species level to future adverse cardiovascular outcome adjusting for type 2diabetes only. (DOCX)

Table S4 Relation of baseline triglycerides species level to future adverse cardiovascular outcome adjusting for Framingham risk factors. (DOCX)
Table S5  Estimated q-values of the tests performed to study the association between CVD risk factors and the lipid species.

(DOCX)

Table S6  Relation between 23 validated coronary artery disease associated gene variants and baseline plasma lipid metabolites level.

(DOCX)

Table S7  The risk allele of 8 of the validated coronary artery disease associated gene variants shows significant association with the baseline plasma level of several lipid species.

(DOCX)

References